10-Q quarterly report · filed Nov 5, 2026

IRONWOOD PHARMACEUTICALS INC (IRWD) Q3 2026 10-Q Quarterly Report

Short answer

IRONWOOD PHARMACEUTICALS INC (IRWD) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $133M (up 9.0% year over year) with net income of $60M.

Q3 2026 key financials · XBRL

Revenue
$133M
+9.0% YoY · +17.7% QoQ
Net income
$60M
+49.3% YoY · +16.7% QoQ
Operating margin
70.0%
EPS (diluted)
$0.36
+44.0% YoY · +16.1% QoQ

Source: XBRL data from the IRONWOOD PHARMACEUTICALS INC (IRWD) Q3 2026 10-Q on SEC EDGAR. USD.

IRONWOOD PHARMACEUTICALS INC Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $133.0M, up $11.0M YoY, driven by LINZESS U.S. net-profit share
  • Operating margin 70.0% vs 61.8% YoY, with operating income $93.1M vs $75.5M
  • Apraglutide R&D $25.2M, up from $17.8M, the largest pipeline expense
  • Cash $86.4M; operating cash flow $130.8M, financing outflow $259.7M
  • STARS-2 recruiting; regulatory filing for apraglutide planned in 2029, subject to results

Risk Factors

  • No material risk-factor changes disclosed; Item 1A contains no substantive risk discussion
  • Partner concentration: AbbVie accounted for $132.1 million of $132.7 million accounts receivable
  • Regulatory and legal exposure: Ferring settlement requires remaining $5.0 million payment by December 31, 2026
  • Liquidity risk: cash declined to $86.4 million while revolving debt remained $325.0 million
  • Commercial concentration: LINZESS U.S. collaboration generated $344.2 million of nine-month revenue through AbbVie

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other IRONWOOD PHARMACEUTICALS INC quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.